Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes.

24 авг. 2024 г. · In the SELECT trial, the largest study of GLP-1 receptor agonists to date, we evaluated the effect of semaglutide in 4286 patients with a ...

7 дек. 2023 г. · Semaglutide reduced cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease who don't have diabetes.

19 дек. 2023 г. · To evaluate if semaglutide 2.4 mg subcutaneously once weekly is superior to placebo when added to standard of care for preventing major adverse cardiovascular ...

13 мая 2024 г. · “SELECT was a well conducted randomised controlled trial which looked at the effects of semaglutide on cardiovascular disease events in people ...

13 мая 2024 г. · In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17604 adults with ...

24 авг. 2024 г. · Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults ...

3 нояб. 2024 г. · New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease ...

11 нояб. 2023 г. · The SELECT Trial GLP-1 receptor agonists have been proven to reduce body weight and lessen CV risk in patients with type 2 diabetes, but—until ...